Sign In
Buy BCYC
$4.20
-0.1000 (-2.33%)
At Close: Jun 03, 2026
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC
10:00am, Thursday, 11'th Dec 2025
NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bicycle Therapeutics plc ("Bicycle" or the "Company") (NASDAQ: BCYC). Such investors are advi
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Brokerages
01:28am, Monday, 01'st Dec 2025
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has received an average recommendation of "Hold" from the thirteen brokerages that are presently covering the stock, MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC
10:00am, Thursday, 20'th Nov 2025
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bicycle Therapeutics plc ("Bicycle" or the "Company") (NASDAQ: BCYC). Such investors are adv
ATTENTION BCYC Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky
03:09pm, Tuesday, 18'th Nov 2025
New York, New York--(Newsfile Corp. - November 18, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Bicycle Therapeutics plc ("Bicycle Therapeutics plc") (NASDAQ:
Acadian Asset Management LLC Buys 572,439 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC
03:15am, Friday, 14'th Nov 2025
Acadian Asset Management LLC grew its stake in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC) by 454.1% during the undefined quarter, according to the company in its most recent 13F filing with
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
04:05pm, Wednesday, 12'th Nov 2025
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
07:00am, Thursday, 30'th Oct 2025
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc
Bicycle Therapeutics: Looking For Their Niche, Addressing Cash Burn
08:36am, Wednesday, 15'th Oct 2025
Bicycle Therapeutics (BCYC) remains a compelling investment, trading below cash value despite promising early data for its lead asset, zelenectide pevedotin. Zelenectide pevedotin shows comparable eff
Bicycle Therapeutics Plc (BCYC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
12:06pm, Tuesday, 09'th Sep 2025
Bicycle Therapeutics plc (NASDAQ:BCYC ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Kevin Lee - CEO & Executive Director Jennifer Perry -
Bicycle Therapeutics Strengthens Board of Directors with New Appointments
04:05pm, Monday, 08'th Sep 2025
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc
Bicycle (BCYC) Q2 Revenue Falls 69%
07:56am, Friday, 08'th Aug 2025
Bicycle (BCYC) Q2 Revenue Falls 69%
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
07:00am, Friday, 08'th Aug 2025
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 02'nd Jul 2025
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on July 1, 2025, the Compensation Committee of the company's Board of Directors granted to e
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 03'rd Jun 2025
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on June 2, 2025, the Compensation Committee of the company's Board of Directors granted to s
